Haematologica最新文献

The real world of acute lymphoblastic leukemia. 急性淋巴细胞白血病的真实世界。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2024.286346

Mark R Litzow

引用次数: 0

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting. 基于 Venetoclax 的急性髓性白血病治疗中的预后分层：在真实世界环境中测试的分子预后风险特征。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2024.285934

Gaia Ciolli, Matteo Piccini, Francesco Mannelli, Giacomo Gianfaldoni, Barbara Scappini, Laura Fasano, Francesca Crupi, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Giada Rotunno, Fabiana Pancani, Leonardo Signori, Chiara Maccari, Fiorenza I Vanderwert, Paola Guglielmelli, Alessandro M Vannucchi

引用次数: 0

Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial. 龙卡素单抗替西林在中国复发或难治性弥漫大B细胞淋巴瘤患者中的应用：一项多中心、开放标签、单臂II期试验。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2024.284973

Ningjing Lin, Xiuhua Sun, Hui Zhou, Liqun Zou, Keshu Zhou, Lihong Liu, Haiyan Yang, Kai Hu, Qingqing Cai, Yao Liu, Jie Jin, Liling Zhang, Wenyu Li, Ye Guo, Wei Yang, Feng Luo, Zhenguang Wang, Rong Zhu, Lei Yang, Dan Song, Yuqin Song, Jun Zhu

{"title":"Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.","authors":"Ningjing Lin, Xiuhua Sun, Hui Zhou, Liqun Zou, Keshu Zhou, Lihong Liu, Haiyan Yang, Kai Hu, Qingqing Cai, Yao Liu, Jie Jin, Liling Zhang, Wenyu Li, Ye Guo, Wei Yang, Feng Luo, Zhenguang Wang, Rong Zhu, Lei Yang, Dan Song, Yuqin Song, Jun Zhu","doi":"10.3324/haematol.2024.284973","DOIUrl":"https://doi.org/10.3324/haematol.2024.284973","url":null,"abstract":"Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Loncastuximab tesirine (Lonca), an antibody conjugate targeting CD19, has demonstrated significant clinical benefit in R/R DLBCL in a global phase 2 LOTIS-2 study. In the China bridging pivotal phase 2 OL-ADCT-402-001 study, eligible patients aged ≥18 years with R/R DLBCL who had failed ≥ 2 lines of systemic therapies were enrolled and treated with Lonca every 3 week with 150 μg/kg for 2 cycles; then 75 μg/kg for subsequent cycles (up to 1 year). The primary endpoint was overall response rate (ORR) assessed by independent review committee. Primary analyses for efficacy and safety were performed on the patients who received at least one treatment and had at least 6 months of follow-up following an initial documented response. As of data-cutoff, 64 patients received Lonca (median: 4.0 cycles [range: 1 to 17]). The median number of prior lines of therapies was 3.0 (range: 2 to 12). The ORR was 51.6% (95% CI: 38.7% to 64.2%), and the complete response rate was 23.4%. Hematological events accounted for the majority of the most common (≥15%) Grade ≥3 treatment-emergent adverse events (TEAEs), in which increased gamma glutamyltransferase (25.0%), and hypokalaemia (18.8%) also were reported. Serious TEAEs were reported in 35 of 64 patients with 4 fatal TEAEs. In conclusion, Lonca monotherapy demonstrated clinically meaningful efficacy and was well-tolerated in heavily pretreated Chinese patients with R/R DLBCL, which was consistent with the results of the LOTIS-2 study in Caucasian patients.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy. 原发性中枢神经系统淋巴瘤患者接受 CD19 靶向嵌合抗原受体 T 细胞疗法后的疗效。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2024.285613

Santiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, Siddhartha Ganguly, Praveen Ramakrishnan Geethakumari, Sanghee Hong, Adriana Malone, Hemant Murthy, Attaphol Pawarode, Alejandro R Sica, Melhem Solh, Celalettin Ustun, Mazyar Shadman, Craig S Sauter, Mehdi Hamadani, Alex F Herrera, Catherine J Lee

引用次数: 0

Adverse prognostic impact of KIT exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with RUNX1::RUNX1T1. 在RUNX1::RUNX1T1小儿急性髓性白血病患者中，尽管流式细胞检测可测量残留病为阴性，但KIT第17外显子突变对预后有不利影响。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2024.286243

Shota Kato, Shin-Ichi Tsujimoto, Jun Matsubayashi, Shotaro Iwamoto, Hidefumi Hiramatsu, Yusuke Okuno, Tatsuya Kamitori, Kentaro Ohki, Takao Deguchi, Nobutaka Kiyokawa, Motohiro Kato, Junko Takita, Shiro Tanaka, Souichi Adachi, Daisuke Tomizawa, Norio Shiba

引用次数: 0

Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial. 阿卡布替尼联合苯达莫司汀和利妥昔单抗对治疗无效或复发/难治套细胞淋巴瘤患者的安全性和有效性：Ib期试验。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2023.284896

Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chuan Wun, Wojciech Jurczak, Stephen D Smith

{"title":"Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial.","authors":"Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chuan Wun, Wojciech Jurczak, Stephen D Smith","doi":"10.3324/haematol.2023.284896","DOIUrl":"https://doi.org/10.3324/haematol.2023.284896","url":null,"abstract":"This multicenter, open-label, phase 1b study (ACE-LY-106) assessed the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-naive (TN) and relapsed or refractory (R/R) mantle cell lymphoma (MCL). Patients received acalabrutinib from cycle 1 until disease progression or treatment discontinuation, bendamustine on days 1 and 2 of each cycle for up to 6 cycles, and rituximab on day 1 of each cycle for 6 cycles, continuing every other cycle from cycle 8 for 12 additional doses (TN cohort). Eighteen patients enrolled in the TN and 20 in the R/R cohort. Median duration of exposure to acalabrutinib was 34.0 and 14.6 months in the TN and R/R cohorts, respectively. No new safety risks were identified, and most adverse events (AEs) were grades 1 or 2. Thirteen patients from the TN cohort (72.2%) and 17 patients from the R/R cohort (85.0%) reported grade 3-4 AEs, most commonly neutropenia (TN: 38.9%, R/R: 50.0%). AEs leading to death were pneumonitis (n=1, TN cohort), COVID-19, and cerebrospinal meningitis (n=1 each, R/R cohort). Overall response was 94.4% and 85.0% in the TN and R/R cohorts, respectively; complete response rates were 77.8% and 70.0%, respectively. After a median follow-up of 47.6 months, median progression-free survival (PFS) and overall survival (OS) were not reached in the TN cohort. After a median follow-up of 20.4 months, median PFS was 28.6 months and OS was not reached in the R/R cohort. Results indicate that ABR was safe and efficacious, supporting further study in patients with TN MCL. ClinicalTrials.gov identifier: NCT02717624.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment. 结节性淋巴细胞为主的霍奇金淋巴瘤：疾病生物学、风险分层和治疗方面的进展。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2024.285903

Ross T Salvaris, Benjamin M Allanson, Graham Collins, Chan Cheah

引用次数: 0

Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen. 对于高风险首次复发B细胞急性淋巴细胞白血病患儿，无论采用哪种治疗方案，Blinatumomab的移植后疗效均优于化疗。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2024.285837

Christina Peters, Angela Bruno, Carmelo Rizzari, Alessandra Brescianini, Arend Von Stackelberg, Christin Linderkamp, Yi Zeng, Gerhard Zugmaier, Franco Locatelli

引用次数: 0

BCAT1 is a NOTCH1 target and sustains the oncogenic function of NOTCH1. BCAT1 是 NOTCH1 的靶标，可维持 NOTCH1 的致癌功能。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2024.285552

Valeria Tosello, Ludovica Di Martino, Adonia E Papathanassiu, Silvia Dalla Santa, Marco Pizzi, Lara Mussolin, Jingjing Liu, Pieter Van Vlierberghe, Erich Piovan

{"title":"BCAT1 is a NOTCH1 target and sustains the oncogenic function of NOTCH1.","authors":"Valeria Tosello, Ludovica Di Martino, Adonia E Papathanassiu, Silvia Dalla Santa, Marco Pizzi, Lara Mussolin, Jingjing Liu, Pieter Van Vlierberghe, Erich Piovan","doi":"10.3324/haematol.2024.285552","DOIUrl":"https://doi.org/10.3324/haematol.2024.285552","url":null,"abstract":"High levels of branched-chain amino acid (BCAA) transaminase 1 (BCAT1) have been associated with tumor aggressiveness and drug resistance in several cancer types. Nevertheless, the mechanistic role of BCAT1 in T-cell acute lymphoblastic leukemia (T-ALL) remains uncertain. We provide evidence that Bcat1 was over-expressed following NOTCH1-induced transformation of leukemic progenitors and that NOTCH1 directly controlled BCAT1 expression by binding to a BCAT1 promoter. Further, using a NOTCH1 gain-of-function retroviral model of T-ALL, mouse cells genetically deficient for Bcat1 showed defects in developing leukemia. In murine T-ALL cells, Bcat1 depletion or inhibition redirected leucine metabolism towards production of 3-hydroxy butyrate (3-HB), an endogenous histone deacetylase inhibitor. Consistently, BCAT1 depleted cells showed altered protein acetylation levels which correlated with a pronounced sensitivity to DNA damaging agents. In human NOTCH1-dependent leukemias, high expression levels of BCAT1 may predispose to worse prognosis. Therapeutically, BCAT1 inhibition specifically synergized with etoposide to eliminate tumors in patient-derived xenograft models suggesting that BCAT1 inhibitors may have a part to play in salvage protocols for refractory T-ALL.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis. 可溶性血栓调节蛋白和活化蛋白 C 对创伤动态止血功能的影响：聚焦凝血酶生成和血块溶解。

IF 8.2 1区医学

Haematologica Pub Date : 2024-09-05 DOI: 10.3324/haematol.2024.285951

Nicola S Curry, Jeries Abu-Hanna, Gael B Morrow, Robin Choudhury, Michael Laffan

{"title":"Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis.","authors":"Nicola S Curry, Jeries Abu-Hanna, Gael B Morrow, Robin Choudhury, Michael Laffan","doi":"10.3324/haematol.2024.285951","DOIUrl":"https://doi.org/10.3324/haematol.2024.285951","url":null,"abstract":"Trauma induced coagulopathy (TIC) describes a complex set of coagulation changes affecting severely injured patients. The thrombomodulin-protein C axis is believed to be central to the evolution of TIC. Soluble thrombomodulin (sTM) levels are elevated after injury. Our objectives were to explore whether sTM (at concentrations found in patients after injury) plays an important role in TIC, and specifically to evaluate the effect of sTM and activated protein C (APC) on thrombin generation (TG) and clot lysis time (CLT). Plasma from healthy volunteers was spiked with rising concentrations of sTM and APC and the effects on TG and CLT were analysed. Plasma samples from a cohort of trauma patients were evaluated using TG and CLT, and results correlated to clinical parameters and FVIII, FV, APC, sTM and fibrinolytic measures. Increasing sTM concentrations in volunteer plasma led to reductions in ETP and prolongation of 50% CLT times, in a dose dependent manner. No effect on TG or CLT was seen with rising APC concentrations. In 91 trauma patients, higher sTM values were associated with greater, rather than reduced, ETP (median 1483 vs. 1681 nM/min) and longer 50% CLT times (41.9 vs. 54.0 mins). In conclusion, sTM concentrations, across trauma ranges, impact both TG and 50% CLT times, unlike APC. Despite increased circulating sTM levels, the overriding dynamic coagulation effects seen after injury are: (a) accelerated thrombin generation and (b) increased rates of fibrinolysis. We find no evidence for sTM as the major determinant of the coagulation changes seen in early TIC.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0